August 11, 2011
Paul E. Sax, M.D., is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston.
One famous HIV clinician/clinical researcher likens co-formulated TDF/FTC/EFV (Atripla) to a "Godzilla," so dominant has the treatment become as initial therapy for HIV. He bases his comments on this study done at his institution, showing that in 2007, fully 85% of patients starting treatment in their clinic began TDF/FTC/EFV.
Does this big lizard of a regimen now have a competitor? Maybe:
On August 10, 2011, FDA approved Complera, a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of CompleraTM is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.
A couple of quick thoughts as I get used to the name:
Isn't it odd that pronunciation of these new drugs is often a mystery? I'm still not sure whether it's etra-VIR-ine or e-TRA-virine, IN-telence or In-TEL-ence, and is "Edurant" pronounced EE-durant or EH-durant or ee-DUR-ant?
As for Complera, I'll assume the accent is on the second syllable until I hear otherwise.
Paul Sax is Clinical Director of Infectious Diseases at Brigham and Women's Hospital. His blog HIV and ID Observations is part of Journal Watch, where he is Editor-in-Chief of Journal Watch AIDS Clinical Care.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.